新华制药：醋酸泼尼松龙化学原料药上市申请获批准

Core Viewpoint - The company, Xinhua Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval notification allows the company to market Acetate Prednisone as a chemical raw material [1] - This product is indicated for various conditions including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, neutropenia, adrenal insufficiency, severe dermatitis, and acute leukemia [1] - Acetate Prednisone is also utilized in the comprehensive treatment of certain infections [1]